Company / Net Debt per Share
Viridian Therapeutics, Inc.\DE Net Debt per Share History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$8.61
FY2024
5-year range
-$16.53 / -$8.61
FY2020-FY2024
Trend
+15.8%
vs FY2023
Sector context
#80 of 82
Health Care
What the data says
Among 82 Health Care companies, Viridian Therapeutics, Inc.\DE is in the top 2% for net debt per share. Net Debt per Share has increased for 3 consecutive years, from $-16.53 in FY2021 to $-8.61 in FY2024.
Based on SEC 10-K filings.
-8.61 in FY2024.
Increased from $-13.09 to $-8.61 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 82This company -$8.61 Sector average $13.70
▼
-162.8% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's net debt per share has grown for 3 consecutive years.
- In FY2024, net debt per share increased 15.8% year-over-year.
- Ranks #80 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$8.61 | +15.8% |
| FY2023 | -$10.22 | +21.9% |
| FY2022 | -$13.09 | +20.8% |
| FY2021 | -$16.53 | - |
| FY2020 | - | - |
| FY2019 | -$9.16 | -1099.2% |
| FY2018 | -$0.76 | +98.3% |
| FY2017 | -$44.91 | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026